Skip to main content
NRXP
NASDAQ Life Sciences

NRX Pharmaceuticals Appoints Joseph M. Casper as Chief Operating Officer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.12
Mkt Cap
$63.651M
52W Low
$1.58
52W High
$3.84
52W Position info
34% above low
Off High info
45% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

NRXP sits 34% above its 52-week low of $1.58 on light trading volume (0.3× avg).

Summary

NRX Pharmaceuticals appointed Joseph M. Casper, a veteran healthcare executive, as Chief Operating Officer, bolstering its leadership team amidst recent compliance concerns.


Key Events · Executive and Board Changes · NRXP

  • New Chief Operating Officer Appointed

    Joseph M. Casper, age 75, was appointed as Chief Operating Officer, effective January 27, 2026.

  • Extensive Healthcare Experience

    Mr. Casper brings 35 years of experience, including leadership roles at Deloitte, First Consulting Group, Kaiser Permanente, and Anthem, and co-invented an early medical record aggregation platform.

  • Compensation Package Details

    His compensation includes an annual base salary of $250,000, a 25% bonus subject to milestones, and a grant of 100,000 stock options vesting over time.

  • Follows Nasdaq Compliance Notice

    This appointment follows a recent Nasdaq notice on January 16, 2026, regarding the company's failure to hold its annual meeting.


Analysis · NRXP · Life Sciences

NRX Pharmaceuticals has appointed Joseph M. Casper, a seasoned healthcare executive with 35 years of experience, as its new Chief Operating Officer. This strategic hire strengthens the company's leadership team, particularly in light of its recent Nasdaq notice regarding the failure to hold an annual meeting on January 16, 2026. Casper's extensive background in healthcare operations, consulting, and technology, including roles at major organizations like Kaiser Permanente and Anthem, suggests a focus on operational efficiency and strategic growth. His appointment could be a positive step towards addressing governance and operational challenges and improving investor confidence.

At the time of this filing, NRXP was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.7M. The 52-week trading range was $1.58 to $3.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Jul 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $3.59 info
Change: -$0.835 (-19%) info
Market Cap: $148.479M info
NRXP
Jun 25, 2026, 5:12 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.62
Real-time Price: $3.59 info
Change: -$0.0284 (-0.78%) info
Market Cap: $148.479M info
NRXP
Jun 24, 2026, 1:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $3.59 info
Change: -$0.120 (-3%) info
Market Cap: $148.479M info
NRXP
Jun 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $3.59 info
Change: -$0.3901 (-10%) info
Market Cap: $148.479M info
NRXP
Jun 04, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $3.59 info
Change: -$0.4106 (-10%) info
Market Cap: $148.479M info